Emergent BioSolutions Inc (EBS)
9.48
+0.08
(+0.85%)
USD |
NYSE |
Nov 22, 16:00
9.41
-0.07
(-0.74%)
After-Hours: 20:00
Emergent BioSolutions Cash from Investing (Quarterly): 112.00M for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 112.00M |
| June 30, 2024 | -4.60M |
| March 31, 2024 | -10.80M |
| December 31, 2023 | -11.40M |
| September 30, 2023 | -18.90M |
| June 30, 2023 | 257.70M |
| March 31, 2023 | -15.10M |
| December 31, 2022 | -45.40M |
| September 30, 2022 | -271.60M |
| June 30, 2022 | -32.10M |
| March 31, 2022 | -32.20M |
| December 31, 2021 | -45.80M |
| September 30, 2021 | -55.20M |
| June 30, 2021 | -67.00M |
| March 31, 2021 | -56.10M |
| December 31, 2020 | -36.90M |
| September 30, 2020 | -45.70M |
| June 30, 2020 | -45.10M |
| March 31, 2020 | -24.20M |
| December 31, 2019 | -36.10M |
| September 30, 2019 | -15.30M |
| June 30, 2019 | -24.10M |
| March 31, 2019 | -21.40M |
| December 31, 2018 | -848.50M |
| September 30, 2018 | -26.10M |
| Date | Value |
|---|---|
| June 30, 2018 | -11.00M |
| March 31, 2018 | -11.60M |
| December 31, 2017 | -207.52M |
| September 30, 2017 | -12.78M |
| June 30, 2017 | -9.301M |
| March 31, 2017 | -20.30M |
| December 31, 2016 | -19.96M |
| September 30, 2016 | -17.00M |
| June 30, 2016 | -21.03M |
| March 31, 2016 | -18.21M |
| December 31, 2015 | -11.83M |
| September 30, 2015 | -13.95M |
| June 30, 2015 | -10.60M |
| March 31, 2015 | -9.082M |
| December 31, 2014 | -17.26M |
| September 30, 2014 | -5.221M |
| June 30, 2014 | -4.81M |
| March 31, 2014 | -182.76M |
| December 31, 2013 | -9.354M |
| September 30, 2013 | -44.42M |
| June 30, 2013 | -6.444M |
| March 31, 2013 | -7.679M |
| December 31, 2012 | -12.90M |
| September 30, 2012 | -10.02M |
| June 30, 2012 | -8.592M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-271.60M
Minimum
Sep 2022
257.70M
Maximum
Jun 2023
-24.22M
Average
-34.15M
Median
Cash from Investing (Quarterly) Benchmarks
| Abbott Laboratories | -594.00M |
| Tonix Pharmaceuticals Holding Corp | -0.009M |
| Geovax Labs Inc | -0.0207M |
| SIGA Technologies Inc | -0.0224M |
| Chimerix Inc | 28.32M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 153.70M |
| Cash from Financing (Quarterly) | -180.30M |
| Free Cash Flow | 138.10M |
| Free Cash Flow Per Share (Quarterly) | 2.660 |
| Free Cash Flow to Equity (Quarterly) | 347.50M |
| Free Cash Flow to Firm (Quarterly) | 154.59M |
| Free Cash Flow Yield | 27.42% |